TNFRSF8 and anaplastic large cell lymphoma: The efficacy of vinblastine in relapsed/refractory ALCL established precedence for the use of tubule inhibition, and preclinical data demonstrated higher potency using brentuximab vedotin versus vinblastine against CD30+ cell lines (24–26).